Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Asset Writedowns and Impairment (2017 - 2021)

Celldex Therapeutics (CLDX) has 4 years of Asset Writedowns and Impairment data on record, last reported at $3.5 million in Q3 2021.

  • For Q3 2021, Asset Writedowns and Impairment changed N/A year-over-year to $3.5 million; the TTM value through Sep 2021 reached $21.5 million, changed N/A, while the annual FY2021 figure was $3.5 million, 80.56% down from the prior year.
  • Asset Writedowns and Impairment reached $3.5 million in Q3 2021 per CLDX's latest filing, down from $14.5 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $14.5 million in Q4 2020 and bottomed at $1.8 million in Q1 2019.
  • Average Asset Writedowns and Impairment over 4 years is $7.0 million, with a median of $5.2 million recorded in 2018.
  • The widest YoY moves for Asset Writedowns and Impairment: up 84.75% in 2019, down 84.75% in 2019.
  • A 4-year view of Asset Writedowns and Impairment shows it stood at $6.9 million in 2018, then plummeted by 73.83% to $1.8 million in 2019, then soared by 705.56% to $14.5 million in 2020, then tumbled by 75.86% to $3.5 million in 2021.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were $3.5 million in Q3 2021, $14.5 million in Q4 2020, and $3.5 million in Q2 2020.